Subject: Treatment of blood-borne diseases to move into the next development stage

INSIDE THIS NEWSLETTER

  • MIT Europe Innovators Under 35
  • BioFIT, Start-up Slams 
  • J.P. Morgan Healthcare Conference
  • McKinsey & Company Early Stage Investor Conference
  • New Team Member: Flow Cytometry Scientist
  • Technology Explainer Video
  • Meet Our Employee
MediSieve in 2020 
Moving up a gear
2020 is set to be a very exciting year for us here at MediSieve. We are looking to accelerate our product development, focussing on our magnetic particles to treat Sepsis, and plan to reach some important milestones, including in vivo validation of the Sepsis solution in animal trials and a first-in-man safety study for the MediSieve Magnet and Filter. We are also planning to attend a multitude of important events to further raise awareness and expand our network. We are also planning a number of developments on the business side that will contribute to MediSieve’s commercial success, leading to a fundraising currently planned for Q3 2020.


 

MediSieve's CEO on MIT Innovators Under 35
George Frodsham, our founder and CEO, was recently listed among MIT Innovators Under 35 Europe. Every year MIT Technology Review selects the most innovative entrepreneurs who are developing new technologies to help solve the world's biggest problems. This recognition makes George part of a global community of innovators, pioneers and social changemakers curated by MIT Technology Review. It is a further validation of our work and a great opportunity to raise further awareness of MediSieve. 
Read more here:
https://www.innovatorsunder35.com/the-list/george-frodsham/

Most Innovative Start-up at BioFit
We finished 2019 with another prestigious award: MediSieve was selected as the most innovative start-up at the BioFIT event in Marseille. BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovations in the Life Sciences. It is also an important marketplace for European pre-seed, seed and Series A investment.
Read more: https://www.biofit-event.com/2019-pitchers/
MediSieve Attends Major Investor Conferences
In the past few months, we have had the chance to meet top-tier MedTech and BioTech investors. Our CEO George Frodsham was invited to Boston present our magnetic blood filtration technology during the 3d Annual Early Stage Investor Conference (ESIC) hosted by McKinsey & Company in December 2019. In early January we also travelled to San Francisco to attend the 38th Annual J.P. Morgan Healthcare Conference, the world's leading healthcare and BioTech event.  
Learn more where to meet us: https://www.linkedin.com/company/9257287
New Hire: Flow Cytometry Scientist 
This January we welcomed a new team member: Tobia Lana joined MediSieve as Flow Cytometry Scientist. He will be working alongside Kerstin Stegmann, our in-house Immunologist, to help develop and validate our magnetic particle products. His work will focus on the biocompatibility and safety aspects of our devices, to better understand how they interact with blood.
Follow us for more company insights: https://twitter.com/MediSieve
New Technology Explainer Video 
We have recently released a new video explaining in detail how our technology works. Watch it to learn how our magnetic particles attach to specific disease targets in the bloodstream, and how the technology varies for different diseases. 
Watch our video: https://www.youtube.com/watch?v=5BuddaOSSEg&t=3s
MediSieve Faces 
MediSieve is working on creating a novel blood filtration technology that will be the first of its kind. But what truly sets us apart from other companies is our people. Meet the individuals who are transforming our dream of eliminating the burden of blood-borne diseases into reality:
Jon Kelly
QA/RA Analyst 
Nationality: British
Joined: May 2019

What are your responsibilities within MediSieve?
- My responsibilities within MediSieve involve creating the Quality Management System in order to get ISO13485 certification, and helping to create the technical files for our products so that we can obtain a CE mark and FDA approval to market the device.

What originally drew you to MediSieve?
- I was initially drawn into MediSieve by how incredible the technology is and the sheer potential the device has to change the lives of so many for the better. I've been working in the Medical Devices industry for over 5 years and in my career so far I've seen that many medical devices on the market do not have the amazing impact that magnetic blood filtration could have on the lives of the vulnerable. Furthermore, having spent most of my time working for international corporations, I find working for a start-up and the various experiences and challenges it brings so refreshing.

What do you like most about working here?
- I really enjoy how entrepreneurial the team are and just how focussed everyone is. During the long process of bringing a medical device to the market it's easy to lose sight of the end goal through day to day activities. At MediSieve I can see that everyone still has their sights on improving the lives of so many through this device.

What are your personal and professional goals for 2020?
My professional goal is for MediSieve to be ISO13485 certified by the end of 2020. I also aim to work to have our technical documentation for submission to our Notified Body for CE Mark submission. Personally, I am going to take part in another triathlon in 2020, and hope to beat my times from 2019 in each discipline. I am also aiming to do as many cycling events as I can in 2020.

"Imagine a world where doctors are able to target and remove infected cells, pathogens, toxins, or even viruses directly from a patient’s bloodstream."
You may unsubscribe or change your contact details at any time.